Skip to main content
Top
Published in: Cardiovascular Drugs and Therapy 3/2016

Open Access 01-06-2016 | ORIGINAL ARTICLE

Paclitaxel-Coated Balloons: Investigation of Drug Transfer in Healthy and Atherosclerotic Arteries – First Experimental Results in Rabbits at Low Inflation Pressure

Authors: Nicola Stolzenburg, Janni Breinl, Stephanie Bienek, Milosz Jaguszewski, Melanie Löchel, Matthias Taupitz, Ulrich Speck, Susanne Wagner, Jörg Schnorr

Published in: Cardiovascular Drugs and Therapy | Issue 3/2016

Login to get access

Abstract

Purpose

Beyond antiproliferative properties, paclitaxel exhibits anti-inflammatory activity, which might be beneficial in the local treatment of nonocclusive coronary artery disease. Paclitaxel release and tissue concentrations after paclitaxel-coated balloon treatment using different pressures have not been investigated so far. The aim of the study was to investigate in an atherosclerotic rabbit model whether drug transfer from paclitaxel-coated balloons into the vessel wall is affected by the presence of atherosclerotic lesions and to which extent it depends on the inflation pressure used.

Methods

Paclitaxel-coated balloons (3.5 μg/mm2 paclitaxel) were inflated with pressures of 1, 2, or 6 atm (60s) in healthy (n = 39) and atherosclerotic (n = 22) arteries of New Zealand White Rabbits. Paclitaxel content in arterial walls (10 min after interventions) and paclitaxel remaining on balloons after treatment were analyzed using high-performance liquid chromatography.

Results

Median paclitaxel tissue concentrations were 829.3 μg/g (IQR 636.5–1487 μg/g) in healthy and 375.7 μg/g (IQR 169.8–771.6 μg/g) in atherosclerotic arteries (p = 0.0002). The paclitaxel tissue concentration was dependent on inflation pressure (1 atm vs. 2 atm vs. 6 atm) in atherosclerotic arteries (p = 0.0106) but not in healthy arteries (p ≥ 0.05).

Conclusions

Atherosclerotic lesions impede the transfer of paclitaxel into arterial walls. Higher inflation pressures resulted in an increased paclitaxel transfer in atherosclerotic but not in healthy arteries. However, it is assumed that the tissue concentrations achieved with an inflation pressure of 2 atm are potentially effective in this model.
Literature
1.
go back to reference Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. J Am Med Assoc. 2005;294(10):1215–23.CrossRef Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. J Am Med Assoc. 2005;294(10):1215–23.CrossRef
2.
go back to reference Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773–80.CrossRefPubMed Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773–80.CrossRefPubMed
3.
go back to reference Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005;353(7):653–62.CrossRefPubMed Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005;353(7):653–62.CrossRefPubMed
4.
go back to reference Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet. 2004;364(9434):583–91.CrossRefPubMed Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet. 2004;364(9434):583–91.CrossRefPubMed
5.
go back to reference Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119(23):2986–94.CrossRefPubMed Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119(23):2986–94.CrossRefPubMed
6.
go back to reference Schmidt A, Piorkowski M, Werner M, et al. First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome. J Am Coll Cardiol. 2011;58(11):1105–9.CrossRefPubMed Schmidt A, Piorkowski M, Werner M, et al. First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome. J Am Coll Cardiol. 2011;58(11):1105–9.CrossRefPubMed
7.
go back to reference Tepe G, Schmitmeier S, Speck U, Schnorr B, Kelsch B, Scheller B. Advances on drug-coated balloons. J Cardiovasc Surg. 2010;51(1):125–43. Tepe G, Schmitmeier S, Speck U, Schnorr B, Kelsch B, Scheller B. Advances on drug-coated balloons. J Cardiovasc Surg. 2010;51(1):125–43.
8.
go back to reference Byrne RA, Neumann F-J, Mehilli J, et al.. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. The Lancet 2013;381(9865):461–7. Byrne RA, Neumann F-J, Mehilli J, et al.. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. The Lancet 2013;381(9865):461–7.
9.
go back to reference Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118(13):1358–65.CrossRefPubMed Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118(13):1358–65.CrossRefPubMed
10.
go back to reference Kielbassa K, Schmitz C, Gerke V. Disruption of endothelial microfilaments selectively reduces the transendothelial migration of monocytes. Exp Cell Res. 1998;243:129–41.CrossRefPubMed Kielbassa K, Schmitz C, Gerke V. Disruption of endothelial microfilaments selectively reduces the transendothelial migration of monocytes. Exp Cell Res. 1998;243:129–41.CrossRefPubMed
11.
go back to reference Mirzapoiazova T, Kolosova IA, Moreno L, Sammani S, Garcia JG, Verin AD. Suppression of endotoxin-induced inflammation by taxol. Eur Respir J. 2007;30(3):429–35.CrossRefPubMed Mirzapoiazova T, Kolosova IA, Moreno L, Sammani S, Garcia JG, Verin AD. Suppression of endotoxin-induced inflammation by taxol. Eur Respir J. 2007;30(3):429–35.CrossRefPubMed
12.
go back to reference Brahn E, Tang C, Banquerigo ML. Regression of Collagen-induced arthritis with taxol, a microtubule stabilizer. Arthritis Rheum. 1994;37(6):839–45.CrossRefPubMed Brahn E, Tang C, Banquerigo ML. Regression of Collagen-induced arthritis with taxol, a microtubule stabilizer. Arthritis Rheum. 1994;37(6):839–45.CrossRefPubMed
13.
go back to reference Scheller B, Clever YP, Kelsch B, et al. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc Interv. 2012;5(3):323–30.CrossRefPubMed Scheller B, Clever YP, Kelsch B, et al. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc Interv. 2012;5(3):323–30.CrossRefPubMed
14.
go back to reference Cremers B, Speck U, Kaufels N, et al. Drug-eluting balloon: very short-term exposure and overlapping. Thromb Haemost. 2009;101(1):201–6.PubMed Cremers B, Speck U, Kaufels N, et al. Drug-eluting balloon: very short-term exposure and overlapping. Thromb Haemost. 2009;101(1):201–6.PubMed
15.
go back to reference Pósa A, Nyolczas N, Hemetsberger R, et al. Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries. Catheter Cardiovasc Interv. 2010;76(3):395–403.CrossRefPubMed Pósa A, Nyolczas N, Hemetsberger R, et al. Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries. Catheter Cardiovasc Interv. 2010;76(3):395–403.CrossRefPubMed
16.
go back to reference Moreno PR, Purushothaman KR, Fuster V, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation. 2004;110(14):2032–8.CrossRefPubMed Moreno PR, Purushothaman KR, Fuster V, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation. 2004;110(14):2032–8.CrossRefPubMed
17.
go back to reference Moreno PR, Purushothaman KR, Fuster V, O'Connor WN. Intimomedial interface damage and adventitial inflammation is increased beneath disrupted atherosclerosis in the aorta: implications for plaque vulnerability. Circulation. 2002;105(21):2504–11.CrossRefPubMed Moreno PR, Purushothaman KR, Fuster V, O'Connor WN. Intimomedial interface damage and adventitial inflammation is increased beneath disrupted atherosclerosis in the aorta: implications for plaque vulnerability. Circulation. 2002;105(21):2504–11.CrossRefPubMed
18.
go back to reference Xu Q, Dietrich H, Steiner J, et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb Vasc Biol. 1992;12(7):789–99.CrossRef Xu Q, Dietrich H, Steiner J, et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb Vasc Biol. 1992;12(7):789–99.CrossRef
19.
go back to reference Xu Q, Kleindienst R, Waitz W, Dietrich H, Wick G. Increased expression of heat shock protein 65 coincides with a population of infiltrating T lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein 65. J Clin Invest. 1993;91(6):2693–702.CrossRefPubMedPubMedCentral Xu Q, Kleindienst R, Waitz W, Dietrich H, Wick G. Increased expression of heat shock protein 65 coincides with a population of infiltrating T lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein 65. J Clin Invest. 1993;91(6):2693–702.CrossRefPubMedPubMedCentral
20.
go back to reference Lamb DJ, Ferns GA. The magnitude of the immune response to heat shock protein-65 following BCG immunisation is associated with the extent of experimental atherosclerosis. Atherosclerosis. 2002;165(2):231–40.CrossRefPubMed Lamb DJ, Ferns GA. The magnitude of the immune response to heat shock protein-65 following BCG immunisation is associated with the extent of experimental atherosclerosis. Atherosclerosis. 2002;165(2):231–40.CrossRefPubMed
21.
22.
go back to reference Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19(2):267–74.CrossRefPubMed Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19(2):267–74.CrossRefPubMed
23.
go back to reference Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001;7(4):425–9.CrossRefPubMed Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001;7(4):425–9.CrossRefPubMed
24.
go back to reference Celletti FL, Hilfiker PR, Ghafouri P, Dake MD. Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque. J Am Coll Cardiol. 2001;37(8):2126–30.CrossRefPubMed Celletti FL, Hilfiker PR, Ghafouri P, Dake MD. Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque. J Am Coll Cardiol. 2001;37(8):2126–30.CrossRefPubMed
25.
go back to reference Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355(20):2113–24.CrossRefPubMed Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355(20):2113–24.CrossRefPubMed
26.
go back to reference Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358(7):689–99.CrossRefPubMed Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358(7):689–99.CrossRefPubMed
27.
go back to reference Tepe G, Laird J, Schneider P, et al. Drug-coated balloon Versus Standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease. Circulation. 2015;131(5):495–502.CrossRefPubMedPubMedCentral Tepe G, Laird J, Schneider P, et al. Drug-coated balloon Versus Standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease. Circulation. 2015;131(5):495–502.CrossRefPubMedPubMedCentral
28.
go back to reference Hehrlein C, Dietz U, Kubica J, et al. Twelve-month results of a paclitaxel releasing balloon in patients presenting with in-stent restenosis first-in-man (PEPPER) trial. Cardiovasc Revasc Med. 2012;13(5):260–4.CrossRefPubMed Hehrlein C, Dietz U, Kubica J, et al. Twelve-month results of a paclitaxel releasing balloon in patients presenting with in-stent restenosis first-in-man (PEPPER) trial. Cardiovasc Revasc Med. 2012;13(5):260–4.CrossRefPubMed
29.
go back to reference Xu B, Gao R, Wang J, et al. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. JACC Cardiovasc Interv. 2014;7(2):204–11.CrossRefPubMed Xu B, Gao R, Wang J, et al. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. JACC Cardiovasc Interv. 2014;7(2):204–11.CrossRefPubMed
30.
go back to reference Habara S, Iwabuchi M, Inoue N, et al. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Am Heart J. 2013;166(3):527–33.CrossRefPubMed Habara S, Iwabuchi M, Inoue N, et al. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Am Heart J. 2013;166(3):527–33.CrossRefPubMed
31.
go back to reference Clever YP, Cremers B, Speck U, Dietz U, Böhm M, Scheller B. Influence of a paclitaxel coated balloon in combination with a bare metal stent on restenosis and endothelial function: comparison with a drug eluting stent and a bare metal stent. Catheter Cardiovasc Interv. 2014;84(2):323–31.CrossRefPubMed Clever YP, Cremers B, Speck U, Dietz U, Böhm M, Scheller B. Influence of a paclitaxel coated balloon in combination with a bare metal stent on restenosis and endothelial function: comparison with a drug eluting stent and a bare metal stent. Catheter Cardiovasc Interv. 2014;84(2):323–31.CrossRefPubMed
32.
go back to reference Liistro F, Porto I, Angioli P, et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013;128(6):615–21.CrossRefPubMed Liistro F, Porto I, Angioli P, et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013;128(6):615–21.CrossRefPubMed
33.
go back to reference Liistro F, Grotti S, Porto I, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv. 2013;6(12):1295–302.CrossRefPubMed Liistro F, Grotti S, Porto I, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv. 2013;6(12):1295–302.CrossRefPubMed
34.
go back to reference Ali RM, Degenhardt R, Zambahari R, et al. Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus. EuroIntervention. 2011;7(Suppl):KK83–92.CrossRef Ali RM, Degenhardt R, Zambahari R, et al. Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus. EuroIntervention. 2011;7(Suppl):KK83–92.CrossRef
35.
go back to reference Unverdorben M, Kleber FX, Heuer H, et al. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: are lesions clinically stable from 12 to 36 months? EuroIntervention. 2013;9(5):620–8.CrossRefPubMed Unverdorben M, Kleber FX, Heuer H, et al. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: are lesions clinically stable from 12 to 36 months? EuroIntervention. 2013;9(5):620–8.CrossRefPubMed
36.
go back to reference Unverdorben M, Kleber FX, Heuer H, et al. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clin Res Cardiol. 2010;99(3):165–74.CrossRefPubMed Unverdorben M, Kleber FX, Heuer H, et al. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clin Res Cardiol. 2010;99(3):165–74.CrossRefPubMed
37.
go back to reference Worthley S, Hendriks R, Worthley M, et al. Paclitaxel-eluting balloon and everolimus-eluting stent for provisional stenting of coronary bifurcations: 12-month results of the multicenter BIOLUX-I study. Cardiovasc Revasc Med. 2015;16(7):413–7.CrossRefPubMed Worthley S, Hendriks R, Worthley M, et al. Paclitaxel-eluting balloon and everolimus-eluting stent for provisional stenting of coronary bifurcations: 12-month results of the multicenter BIOLUX-I study. Cardiovasc Revasc Med. 2015;16(7):413–7.CrossRefPubMed
38.
go back to reference Schulz A, Hauschild T, Kleber FX. Treatment of coronary de novo bifurcation lesions with DCB only strategy. Clin Res Cardiol. 2014;103(6):451–6.CrossRefPubMed Schulz A, Hauschild T, Kleber FX. Treatment of coronary de novo bifurcation lesions with DCB only strategy. Clin Res Cardiol. 2014;103(6):451–6.CrossRefPubMed
39.
go back to reference Speck U, Scheller B, Abramjuk C, et al. Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology. 2006;240(2):411–8.CrossRefPubMed Speck U, Scheller B, Abramjuk C, et al. Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology. 2006;240(2):411–8.CrossRefPubMed
40.
go back to reference Kelsch B, Scheller B, Biedermann M, et al. Dose response to paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model. Investig Radiol. 2011;46(4):255–63.CrossRef Kelsch B, Scheller B, Biedermann M, et al. Dose response to paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model. Investig Radiol. 2011;46(4):255–63.CrossRef
41.
go back to reference Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110(7):810–4.CrossRefPubMed Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110(7):810–4.CrossRefPubMed
42.
go back to reference Speck U, Cremers B, Kelsch B, et al. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel? Circ Cardiovasc Interv. 2012;5(3):392–400.CrossRefPubMed Speck U, Cremers B, Kelsch B, et al. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel? Circ Cardiovasc Interv. 2012;5(3):392–400.CrossRefPubMed
43.
go back to reference Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vliestra RE, Holmes DR. Restenosis after balloon angioplasty. A practical proliferative model in porcine coronary arteries. Circulation. 1990;82(6):2190–200.CrossRefPubMed Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vliestra RE, Holmes DR. Restenosis after balloon angioplasty. A practical proliferative model in porcine coronary arteries. Circulation. 1990;82(6):2190–200.CrossRefPubMed
44.
go back to reference Schwartz RS, Holmes DR. Pigs, dogs, baboons, and man: lessons for stenting from animal studies. J Interv Cardiol. 1994;7(4):355–68.CrossRef Schwartz RS, Holmes DR. Pigs, dogs, baboons, and man: lessons for stenting from animal studies. J Interv Cardiol. 1994;7(4):355–68.CrossRef
45.
go back to reference Cremers B, Toner JL, Schwartz LB, et al.. Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter. Clin Res Cardiol. 2012;101(6):469–76. Cremers B, Toner JL, Schwartz LB, et al.. Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter. Clin Res Cardiol. 2012;101(6):469–76.
46.
go back to reference Buszman PP, Milewski K, Zurakowski A, et al.. Experimental evaluation of pharmacokinetic profile and biological effect of a novel paclitaxel microcrystalline balloon coating in the iliofemoral territory of swine. Catheter Cardiovasc Interv. 2014;83(2):325–33. Buszman PP, Milewski K, Zurakowski A, et al.. Experimental evaluation of pharmacokinetic profile and biological effect of a novel paclitaxel microcrystalline balloon coating in the iliofemoral territory of swine. Catheter Cardiovasc Interv. 2014;83(2):325–33.
47.
go back to reference Fernández-Parra R, Laborda A, Lahuerta C, et al. Pharmacokinetic study of paclitaxel concentration after drug-eluting balloon angioplasty in the iliac artery of healthy and atherosclerotic rabbit models. J Vasc Interv Radiol. 2015;26(9):1380–7.e1.CrossRefPubMed Fernández-Parra R, Laborda A, Lahuerta C, et al. Pharmacokinetic study of paclitaxel concentration after drug-eluting balloon angioplasty in the iliac artery of healthy and atherosclerotic rabbit models. J Vasc Interv Radiol. 2015;26(9):1380–7.e1.CrossRefPubMed
48.
go back to reference Virmani R, Farb A, Burke AP. Coronary angioplasty from the perspective of atherosclerotic plaque: morphologic predictors of immediate success and restenosis. Am Heart J. 1994;127(1):163–79.CrossRefPubMed Virmani R, Farb A, Burke AP. Coronary angioplasty from the perspective of atherosclerotic plaque: morphologic predictors of immediate success and restenosis. Am Heart J. 1994;127(1):163–79.CrossRefPubMed
50.
go back to reference Saffitz JE, Totty WG, McClennan BL, Gilula LA. Percutaneous transluminal angioplasty. Radiological-pathological correlation. Radiology. 1981;141(3):651–4.CrossRefPubMed Saffitz JE, Totty WG, McClennan BL, Gilula LA. Percutaneous transluminal angioplasty. Radiological-pathological correlation. Radiology. 1981;141(3):651–4.CrossRefPubMed
51.
go back to reference Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5(6):831–40.CrossRefPubMed Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5(6):831–40.CrossRefPubMed
52.
go back to reference Kleber FX, Schulz A, Waliszewski M, et al.. Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty. Clin Res Cardiol. 2015;104(3):217–25. Kleber FX, Schulz A, Waliszewski M, et al.. Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty. Clin Res Cardiol. 2015;104(3):217–25.
53.
go back to reference Siablis D, Kitrou PM, Spiliopoulos S, Katsanos K, Karnabatidis D. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial. JACC Cardiovasc Interv. 2014;7(9):1048–56.CrossRefPubMed Siablis D, Kitrou PM, Spiliopoulos S, Katsanos K, Karnabatidis D. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial. JACC Cardiovasc Interv. 2014;7(9):1048–56.CrossRefPubMed
54.
go back to reference Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur Heart J. 2013;34(10):719–28.CrossRefPubMed Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur Heart J. 2013;34(10):719–28.CrossRefPubMed
Metadata
Title
Paclitaxel-Coated Balloons: Investigation of Drug Transfer in Healthy and Atherosclerotic Arteries – First Experimental Results in Rabbits at Low Inflation Pressure
Authors
Nicola Stolzenburg
Janni Breinl
Stephanie Bienek
Milosz Jaguszewski
Melanie Löchel
Matthias Taupitz
Ulrich Speck
Susanne Wagner
Jörg Schnorr
Publication date
01-06-2016
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 3/2016
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-016-6658-1

Other articles of this Issue 3/2016

Cardiovascular Drugs and Therapy 3/2016 Go to the issue